Arecor Therapeutics secures licensing deal for AT351, pioneering ready-to-dilute critical care therapy

Arecor Therapeutics plc, a globally focused biopharmaceutical company, has entered into an exclusive licensing agreement for AT351, a breakthrough ready-to-dilute (RTD) liquid formulation for critical care therapy. This collaboration, with a subsidiary of one of the world’s largest independent chemicals marketing firms, underscores Arecor’s leadership in innovative drug delivery technologies.

AT351 aims to revolutionise the administration of critical care medicines by offering a simplified, efficient alternative to traditional preparation methods. This partnership represents a major milestone for Arecor, aligning with its strategy to enhance patient outcomes and drive shareholder value through proprietary advancements in therapeutic delivery.

Transforming Critical Care with Innovative RTD Formulations

The AT351 product, while undisclosed in detail, is a widely used therapy in critical care settings. Current formulations require complex storage and preparation processes, consuming valuable time and resources in hospital environments. AT351’s ready-to-dilute liquid format addresses these challenges, offering significant advantages in terms of ease of use, reduced preparation time, and cost efficiency across the supply chain.

The deal builds on a successful formulation collaboration where Arecor applied its proprietary Arestat™ technology. This platform optimises the stability and usability of existing therapies, allowing the development of differentiated products with enhanced patient and provider convenience.

Arecor’s Licensing Strategy and Market Potential

Under the licensing agreement, Arecor has secured an upfront milestone payment, with eligibility for additional development, regulatory, and commercial payments. The deal also includes royalties on global sales of AT351.

The licensee, a pharmaceutical-focused subsidiary of a major chemicals marketing company, will oversee the development, regulatory approval, and commercialisation of AT351 worldwide. The product is set to enter the U.S. Food and Drug Administration’s 505(b)(2) regulatory pathway, with approval anticipated within three years.

This pathway allows for the approval of new formulations of existing drugs, leveraging existing data to streamline regulatory processes. AT351’s advancement in this category positions it as a potential first-to-market innovation, enabling hospitals and healthcare providers to improve efficiency while maintaining patient safety.

Leadership Insights and Long-Term Value Creation

Sarah Howell, Chief Executive Officer of Arecor, emphasised the strategic significance of the deal, highlighting its validation of the company’s proprietary Arestat platform and its ability to drive long-term growth. Howell noted that the partnership demonstrates Arecor’s focus on delivering solutions that not only enhance patient care but also create value for stakeholders.

The AT351 agreement is also a testament to the value of Arecor’s technology-partnering model. By collaborating with global pharmaceutical leaders, the company is accelerating the development of life-changing therapies while maximising the commercial potential of its innovations.

The Future of AT351 in Critical Care

AT351 has the potential to redefine standard practices in critical care, enabling faster, more reliable delivery of essential therapies. Its RTD liquid formulation offers practical benefits for both patients and healthcare providers, positioning it as a vital addition to the therapeutic landscape.

Arecor’s approach combines cutting-edge technology with strategic partnerships, paving the way for transformative products that address unmet medical needs. As the company prepares for regulatory submissions and eventual commercialisation of AT351, it remains at the forefront of driving meaningful advancements in patient care.